Engflag

ESTRACE CREAM

Quick links to important sections

ESTRACE CREAM

ESTRACE CREAM_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ESTRACE CREAM

Property Description
Active ingredient Estradiol (INN)
Form Vaginal Cream (Nonliquefying base)
Pharmacological class Estrogens, Estrogen Derivatives
Common use Local hormone restoration
Origin Bio-identical Sex Hormone

What Type of Medicine is ESTRACE CREAM and What is It Made Of?

ESTRACE CREAM is a specialized, prescription-only brand medication classified pharmacologically as an Estrogen Derivative and presented as a Vaginal Cream dosage form. Its single active component is Estradiol (INN). This preparation is designated for local administration, meaning it is specifically designed to deliver the active substance directly to the target tissue while minimizing widespread absorption into the general bloodstream.

The active component, Estradiol, is a bio-identical sex hormone because its chemical structure is identical to the most potent estrogen naturally produced by the human body. The unique feature of this product is its formulation as a specific, nonliquefying cream base, which supports the localized action of the hormone. The delivery method of applying a cream to the vaginal tissue is a recognized approach for managing localized symptoms arising from hormonal deficiency.

How is Estradiol Cream Used for Hormone Restoration?

This medicine is characterized as local estrogen therapy, a method primarily intended for hormone supplementation to the applied area. The general purpose is hormone restoration, specifically addressing discomforts and structural changes resulting from low estrogen levels (hypoestrogenism) in the vaginal and external genital tissues, particularly in postmenopausal women.

By applying Estradiol directly, the hormone is able to exert its local agonist action, supporting the maintenance and restoration of the health, elasticity, and natural thickness of the vaginal lining. The use of local estrogen preparations is intended to improve the structural integrity of the vaginal epithelium. Consequently, the general benefit of the preparation is the targeted relief of related physical symptoms, such as chronic dryness, burning, and irritation of the local tissues, by correcting the underlying hormone-related tissue changes.

Regulatory References

  1. MedlinePlus, Estradiol Vaginal
  2. PubMed, Systemic and Local Estrogen Therapy

What side effects are possible with ESTRACE CREAM?

The safety profile for Estrace Cream is established by official regulatory authorities, encompassing both expected local reactions and mandatory disclosure of serious, systemic risks associated with the entire class of estrogen hormone therapies.

Official Adverse Reactions and Frequency Classifications

Adverse reactions are classified according to frequency in regulatory documents. Common reactions often involve the Reproductive system and breast disorders (e.g., breast pain or tenderness, vaginal discharge, and localized vaginal irritation or burning). Headache and abdominal pain are also commonly listed.

Less common, but serious, systemic events documented for the estrogen class include Vascular disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (MI). The risk of specific malignancies, including endometrial cancer, breast cancer, and ovarian cancer, is also part of the mandated safety disclosure.

Safety Constraints and Special Population Notes

The medicine is subject to absolute contraindications defined in regulatory labels, prohibiting its use in individuals with conditions such as undiagnosed abnormal uterine bleeding, known estrogen-dependent cancer, a history of thromboembolic disease, or severe hepatic impairment.

Safety data explicitly notes that the risk of serious systemic events, including thromboembolic disease and malignancy, increases with the duration of use. Additionally, the label contains population-specific safety notes, particularly concerning an increased risk of dementia in women aged 65 or older.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Estrace Cream (estradiol vaginal cream) defines the documented manifestations and required emergency actions in the event of suspected overdosage.

Documented Overdose Manifestations

Acute overexposure to estrogen products may result in specific clinical signs. These documented manifestations include common systemic and gastrointestinal disturbances, such as nausea, vomiting, and stomach pain. Other noted symptoms can involve breast pain or tenderness, as well as central nervous system effects like dizziness, drowsiness, and fatigue. A specific regulatory note indicates that withdrawal bleeding may occur in females as a physical sign of overdosage.

Required Emergency Actions

Immediate medical attention is necessary if an overdose is suspected. Government health authorities require that a person exhibiting severe symptoms, such as passing out or experiencing trouble breathing, seek emergency services immediately (Call 911). Otherwise, individuals are instructed to contact a poison control center right away. The management of overdosage consists of the discontinuation of Estrace Cream therapy combined with the institution of appropriate symptomatic care. No specific antidote is mentioned in the official prescribing information. Serious ill effects have not been reported following the acute ingestion of large doses by young children.

Therapeutic Uses of ESTRACE CREAM

What ESTRACE CREAM Treats: Main Uses and Benefits

Estrace Cream is a highly localized prescription therapy used for hormone restoration that helps address structural and symptomatic changes arising from estrogen deficiency, primarily in postmenopausal women. The therapeutic purpose is to provide support that helps ease the overall symptom burden and is relevant in contexts marked by increased discomfort or tension.

Treating Genitourinary Syndrome of Menopause (GSM)

This medication is commonly used to treat Genitourinary Syndrome of Menopause (GSM), which is associated with tissue thinning and loss of structural health in the vulvar and vaginal areas. It provides support that helps with easing symptoms related to localized discomfort and is relevant in contexts marked by increased discomfort or tension. This is considered relevant in conditions where functional stability becomes affected by tissue changes.

Relieving Chronic Vaginal Discomfort and Dyspareunia

Estrace Cream is relevant for managing symptom clusters that may become intense or disruptive, including persistent vaginal dryness, burning, itching, and generalized irritation. It is relevant for managing symptoms that interfere with daily comfort and contributes to improved comfort during periods of heightened symptoms, helping to ease dyspareunia (painful intercourse) and may assist with maintaining functional stability.

Easing Associated Urogenital Symptoms

In situations where patients experience increased discomfort or tension, this therapy is applicable in clinical settings where lower urogenital symptoms—such as urinary frequency, urgency, and a tendency toward recurrent UTIs—are directly linked to estrogen-related atrophy. It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Key Use: Addressing Vaginal Burning Estrace Cream is applied across domains where additional symptomatic support is needed, assisting with symptoms that interfere with daily comfort, such as persistent vaginal burning and itching.

Eligibility and Restrictions for Use

Who Can and Cannot Use ESTRACE CREAM?

Eligibility for Estrace Cream is strictly defined by regulatory authorities and centers on the patient's menopausal status, age, and absence of specific contraindicating medical conditions, as documented in official prescribing information.

Populations Allowed to Use the Medicine

  • Primary Eligible Population: Postmenopausal women seeking local treatment for symptoms related to vulvar and vaginal atrophy (Genitourinary Syndrome of Menopause).
  • Age Eligibility: Use is established for adult and older adult women (postmenopausal).

Absolute Contraindications (Must Not Use)

Official regulatory documents state the cream is absolutely contraindicated in patients with a known or suspected history of the following conditions:

  • Breast cancer or other known or suspected estrogen-dependent neoplasia (except when receiving treatment for metastatic disease).
  • Undiagnosed abnormal genital bleeding.
  • Active or a history of arterial or venous thromboembolic disease (e.g., Deep Vein Thrombosis, Pulmonary Embolism, stroke, myocardial infarction).
  • Known thrombophilic disorders (inherited clotting disorders).
  • Known active hepatic impairment or disease.
  • Known hypersensitivity to any component of the cream.

Age and Physiological Restrictions

  • Pregnancy: The cream is contraindicated during pregnancy due to the risk of fetal harm.
  • Lactation: Use is not recommended as estrogen is excreted in breast milk and may suppress milk production.
  • Pediatric Use: The medicine is not indicated for children; safety and effectiveness have not been established in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Estrace Cream is defined by its metabolic pathway and specific pharmacologic actions documented in regulatory sources.

Metabolic Interactions (Pharmacokinetic) The active ingredient, estradiol, undergoes partial metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration of substances that affect CYP3A4 activity can alter the circulating levels of estradiol.

Interaction Type Examples Official Outcome
Exposure-Reducing (CYP3A4 Inducers) Rifampin, Phenobarbital, Carbamazepine May reduce plasma concentrations of estradiol, potentially resulting in a decrease in therapeutic effect.
Exposure-Increasing (CYP3A4 Inhibitors) Ketoconazole, Erythromycin, Ritonavir May increase plasma concentrations of estradiol, potentially increasing the risk of associated events.

Pharmacodynamic and Substance Interactions Specific pharmacologic agents and substances are noted for interaction-related constraints:

  • Estradiol may diminish the pharmacologic action of co-administered Aromatase Inhibitors.
  • The use of this product is subject to a formal restriction against concurrent use with other systemic Hormone Replacement Therapy (HRT) medicines.
  • The herbal supplement St. John's Wort is documented as a CYP3A4 inducer, and Grapefruit Juice is documented as a CYP3A4 inhibitor, both affecting estradiol exposure.

Summary of Interaction Constraints Regulatory documents establish that the primary interaction constraint is the alteration of estradiol plasma levels by CYP3A4 enzyme modulators. This pharmacokinetic vulnerability is supplemented by a formal restriction against co-use with other systemic HRT due to concerns of excessive exposure. Furthermore, a necessary consideration regarding pharmacologic antagonism exists with Aromatase Inhibitors.

Mechanism of Action

Estradiol, the active pharmaceutical ingredient in ESTRACE CREAM, is a selective agonist for nuclear estrogen receptors (ERs), specifically ER-alpha ( ERalpha) and ER-beta ( ERbeta). Upon local application, the estradiol molecules penetrate the epithelial cell membranes within the targeted tissue and bind to these intracellular receptors, primarily within the cytoplasm and nucleus of the target cells.

The binding of estradiol to the ligand-binding domain of the ER causes a conformational change in the receptor protein. This conformational change facilitates receptor dimerization and subsequent translocation of the activated ER-ligand complex to the cell nucleus. In the nucleus, the complex binds to specific Estrogen Response Elements (EREs) located in the promoter regions of target genes.

This binding event modulates gene transcription by recruiting coactivator or corepressor proteins, leading to changes in the rate of messenger RNA (mRNA) synthesis for specific proteins. The net intracellular consequence is a systemic alteration of protein expression, which influences the proliferation, differentiation, and overall function of hormone-sensitive cells. The resulting system-level physiological modulation is the restoration of biological activity characteristic of the natural endogenous estrogenic steroid, 17beta-estradiol.

Dosage and Administration Information

Administration Scope: Guidelines

The administration of Estrace Cream is strictly intravaginal, delivered locally using the calibrated applicator supplied with the product. This application route is necessary to target the tissues directly, consistent with its formulation as a local estrogen therapy. The protocol specifies that the dose should generally be applied at bedtime to optimize retention.

Dosing Regimens and Frequency

Usage is typically structured in two distinct phases: an initial course followed by a long-term maintenance regimen. The therapy begins with an initial phase where a dose between 2 grams and 4 grams of the cream is applied once daily. This daily application is maintained for a short period, typically one to two weeks.

For long-term use, the regimen transitions into a maintenance phase. The prescribed dose is typically reduced to a range of 1 gram to 2 grams and is applied one to three times per week, often on a pre-defined cyclic schedule. Continuation of this long-term regimen requires formal re-evaluation by a health professional at regular intervals, such as every three to six months.

Procedural and Population Rules

For proper administration, the dose must be measured precisely with the calibrated applicator. The applicator must be cleaned after each use with only mild soap and warm water, with a specific instruction to not boil or use hot water. Regarding population use, use in children is not recommended. Older adults should adhere to the principle of using the lowest effective dose.

Recent Clinical Evidence

Research examining the use of estradiol cream was studied for postmenopausal women experiencing symptoms related to Genitourinary Syndrome of Menopause (GSM). The core evidence consists of Randomized Controlled Trials (RCTs) typically covering defined time periods and systematic reviews. These studies were conducted during periods of increased symptom activity, and research examined patient-reported discomfort, such as the most bothersome symptom (MBS), vaginal burning, and pain during intercourse (dyspareunia).

In these research scenarios, the studies monitored changes in both subjective symptoms and objective biological markers. Objective outcomes included monitoring of the Vaginal Maturation Index (VMI)—a measure of tissue health—and vaginal pH levels, which reflect the local physiological environment. Findings describe patterns observed in the studies related to these measurements. Some trials described patterns in symptom evolution when comparing the cream to an inactive vehicle (placebo) or to other local estrogen products. Research describes how clinical assessment relies on patient-reported outcomes as well as monitoring temporary physiological imbalance within the vaginal tissue. Data reflect patterns associated with the local application of the cream and provide insight into short-term changes observed in trial settings.

The duration of most efficacy trials was limited, typically observing responses over defined time intervals of 7 to 12 weeks. While short-term studies were conducted over defined intervals, long-term effects are not fully established by controlled clinical research. Evidence is limited concerning the required length of observation to characterize sustained patterns.

The initial clinical trials primarily focused on a broad group of postmenopausal women, meaning that results apply only to the populations studied. Data for certain groups remain insufficient, and research does not determine whether an individual will respond similarly to the group patterns described. For populations with specific medical histories, such as women with a history of estrogen-sensitive cancers, limited dedicated study data from randomized trials is available, and certainty remains low. The overall evidence base describes what is known—and what is still uncertain. A key limitation is that trials were limited in size for detecting infrequent or rare systemic events over an extended period.

Key Studies & References

  1. Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis
  2. Genitourinary syndrome of menopause: Common problem, effective treatments

Frequently Asked Questions (FAQ)

Common questions about ESTRACE CREAM (FAQ)

Q: What is the official risk of breast cancer associated with local estrogen cream use?

A: Regulatory documents state that the risk of serious systemic events, including breast cancer, is part of the mandated safety disclosure for all estrogen class therapies. This requirement reflects the known risks of the estrogen class and the need for ongoing safety review, particularly because long-term safety data specific to local products are limited.

Q: Are there any serious risks or a Black Box Warning associated with Estrace Cream according to regulatory bodies?

A: Official product information notes that estrogen products carry warnings for serious risks, including cardiovascular disorders, blood clots, and certain cancers. Regulatory bodies have requested the content of the Boxed Warning—a prominent safety statement on prescription drug labels—be tailored for local estrogen products to accurately reflect their specific benefit/risk profile.

Q: Is it normal to notice a white, creamy discharge or residue after using the cream?

A: Vaginal discharge is listed in official documents as a common adverse reaction to the product. The cream is made with a nonliquefying base to support its localized action, which is consistent with the presence of a residue. This is an observation that may be related to the product's formulation.

Q: What is the success rate for Estrace Cream described in clinical trials?

A: Instead of providing a single 'success rate,' clinical trials describe patterns of improvement in specific objective and subjective measures. These measures include the Vaginal Maturation Index (VMI), which tracks tissue health, and patient-reported symptoms like pain during intercourse. The official product information details these measurements rather than providing a percentage of overall success.

Q: Why do some sources call Estrace Cream a "low-dose" treatment?

A: The product is designated for local administration to treat specific tissues in the vagina, aiming to minimize widespread absorption into the general bloodstream. Pharmacokinetic data indicates that estradiol blood levels are generally lower compared to those seen with systemic hormone replacement therapies. This information serves as the basis for the distinction often made in related literature.

Q: Are there any general expectations for improvement in vaginal dryness after one month of use?

A: Studies on the effectiveness of the cream typically observe responses over defined time intervals of 7 to 12 weeks. While the initial phase of therapy is shorter, the official product summary does not generally provide specific effectiveness results or expectations for the 4-week (one-month) mark.

Q: How does the local application of Estrace Cream differ from a patch or gel in terms of absorption?

A: The local application of Estrace Cream is intended to treat specific, localized symptoms while actively minimizing widespread absorption into the general bloodstream. Systemic forms of estrogen therapy, such as patches or gels, are generally intended for widespread delivery throughout the body.

Q: Can Estrace Cream cause breakthrough bleeding or spotting?

A: Yes, regulatory documents list irregular vaginal bleeding or spotting as a common side effect of the product. This type of bleeding is generally described as unexpected bleeding outside of a patient's normal cycle or pattern.

Q: Do women experience weight gain from using Estrace Cream?

A: Official product information lists weight gain as a common side effect of the product. This observation is based on data collected during clinical trials.

Q: Can I use Estrace Cream while taking an oral antidepressant or other chronic medication?

A: Official product information indicates that the product may be affected by any drug that interferes with the Cytochrome P450 3A4 (CYP3A4) enzyme, which processes the estrogen. This is a general pharmacokinetic vulnerability. Guidance regarding specific drug interactions is determined by a healthcare provider.

Q: Can Estrace Cream be used by pre-menopausal women for certain conditions?

A: Official indications state that the medicine is approved for the treatment of vulvar and vaginal atrophy due to menopause in postmenopausal women. The safety and effectiveness of the cream are not established for use in pre-menopausal women, as the medicine is indicated for postmenopausal women.

Q: Why is a progestin sometimes needed alongside systemic estrogen therapy?

A: Regulatory warnings explain that a progestin is generally added to estrogen therapy in women with an intact uterus (one who has not had a hysterectomy). This is done to help reduce the risk of estrogen-induced endometrial hyperplasia, which is a condition that can be a precursor to endometrial cancer.

Q: Does Estrace Cream cause or worsen urinary incontinence?

A: Studies reviewed by regulatory bodies describe patterns that link local estrogen therapy to improvement in urinary symptoms in postmenopausal patients. However, evidence is generally considered insufficient to determine comprehensive effectiveness for specifically improving or resolving overall urinary incontinence.

Q: Is the estrogen absorbed from Estrace Cream enough to protect bones from osteoporosis?

A: Official indications state that the product is approved solely for the local treatment of vulvar and vaginal atrophy. While systemic estrogen may be approved for osteoporosis prevention, topical vaginal products are generally considered when addressing solely local tissue symptoms.

Q: Why is a patient information leaflet required to be dispensed with Estrace Cream?

A: The FDA mandates that a Patient Information Leaflet (Medication Guide) be dispensed with estrogen-containing products. This is done to provide patients with essential safety information regarding the benefits and risks associated with the medicine.

Q: What is the risk of endometrial hyperplasia with local estrogen cream?

A: Official warnings note that the potential for some systemic exposure exists with local estrogen products. Due to this potential, the risks associated with oral HRT, including endometrial hyperplasia (a condition that can lead to cancer), are included in the product's safety information.

Q: Can Estrace Cream cause mood swings or depression?

A: Adverse events with an unknown incidence have included reported feelings of being sad or empty and episodes of irritability. This information is documented in the product's official adverse reactions section.

How should ESTRACE CREAM be stored and disposed of?

How to Store and Dispose of ESTRACE Cream

The storage and disposal of ESTRACE (estradiol vaginal cream, USP, 0.01%) must strictly follow the conditions defined in official regulatory documents to maintain product integrity and safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at room temperature and protected from temperatures in excess of 40 C (104 F).
Protection Keep the cream from freezing, and store away from excessive light and moisture.
Container Rule Keep the lid of the tube tightly closed when not in use.
Child Safety Keep this and all medications out of the reach of children.

Disposal Requirements

Unused or expired ESTRACE Cream must be disposed of properly. Patients should throw away any unused medicine after the expiration date and are advised to ask their healthcare professional or pharmacist about the correct procedures for discarding medicine that is no longer needed. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of ESTRACE CREAM found in:

A-Z Index: